Axios-Ipsos Poll: Health Affordability Is Shaping the Midterms

Why It Matters

Health‑affordability is emerging as a decisive election issue, forcing both parties to address cost‑reduction policies to win swing voters.

Key Takeaways

• 54% would back candidates supporting direct-to-consumer drug sales
• 71% of Democrats favor reinstating ACA subsidies; only 26% of Republicans
• 72% worried about rising insurance premiums this year
• Cost‑sensitive voters: ages 30‑49, households under $50k
• GLP‑1 obesity drug awareness low despite increased usage

Pulse Analysis

Health‑cost anxiety has resurfaced as a top driver of voter behavior, echoing the pivotal role health policy played in the 2018 and 2022 midterms. The Axios‑Ipsos American Health Index shows that nearly half of respondents will let drug‑price and insurance‑affordability proposals sway their ballot choices, underscoring a broader shift where economic pressures on gas, groceries and everyday expenses translate into political demand for relief. This trend signals that candidates who ignore cost concerns risk alienating a sizable, issue‑focused electorate.

Two policy pillars dominate the conversation: direct‑to‑consumer prescription drug sales and the revival of enhanced ACA marketplace subsidies. Over half of voters—54%—express willingness to support candidates championing platforms like GoodRx or TrumpRx, while roughly 60% back reinstating subsidies that were allowed to lapse at the end of 2025. Although Democrats show overwhelming enthusiasm (71%) for the subsidies, a notable 49% of independents also favor them, suggesting Republicans could weaponize the subsidy debate as a partisan wedge. Campaign strategists will need to balance bipartisan appeal with clear messaging on cost‑saving mechanisms to capture the median voter.

The demographic analysis sharpens the picture: voters aged 30‑49, parents of minors, and households earning under $50,000 are the most price‑sensitive, with 72% expressing concern over rising premiums. Meanwhile, public knowledge of GLP‑1 obesity drugs remains shallow despite a surge in prescriptions, highlighting an information gap that could influence future health‑policy debates. As the midterms approach, the convergence of economic strain and health‑care affordability is set to reshape party platforms, legislative priorities, and ultimately, the electoral map.